Two sides of the medallion: Poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1280-1286

  Van de Schans, S A M ^a   Wymenga, A N M ^b   Van Spronsen, D J ^c,d   Schouten, H C ^e   Coebergh, J W W ^a,f   Janssen Heijnen, M L G ^a,f  

^a Eindhoven Cancer Registry   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Diffuse large B cell lymphoma; Elderly; Population based; Survival; Toxicity; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GERIATRIC CARE; GERIATRIC PATIENT; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT REFUSAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; NEOPLASM STAGING; NETHERLANDS; PREDNISONE; REGISTRIES; STANDARD OF CARE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84860425598     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr411     Document Type: Article

References (35)

1. Ferlay J, Parkin DM, Steliarova Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
2. Curado MP, Edwards B, Shin HR et al. Cancer Incidence in Five Continents, Vol. IX. Lyon, France: International Agency of Research on Cancer Scientific Publications, No 160 2007.
3. Richtlijn non-Hodgkin lymfoom. Alphen ad Rijn: Van Zuiden Communications BV 2004.
4. Sonneveld P, de Ridder M, van der Lelie H et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13: 2530-2539.
5. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
6. Lugtenburg PJ, Sonneveld P, van Putten W et al. Two-weekly CHOP chemotherapy with or without rituximab for the treatmentof diffuse large B-cell lymphoma in high-risk elderly patients: arandomized phase III trial by the Dutch HOVON and Nordic Lymphoma groups. Submitted.
7. Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE et al. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol 2005; 129: 597-606.
8. Maartense E, Hermans J, Kluin-Nelemans JC et al. Elderly patients with non-Hodgkin's lymphoma: population-based results in The Netherlands. Ann Oncol 1998; 9: 1219-1227.
9. Peters FP, Lalisang RI, Fickers MM et al. Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study. Ann Hematol 2001; 80: 155-159.
10. van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE et al. Independent prognostic effect of co-morbidity in lymphoma patients: results of the populationbased Eindhoven Cancer Registry. Eur J Cancer 2005; 41: 1051-1057.
11. Aapro MS, Kohne CH, Cohen HJ, Extermann M. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist 2005; 10: 198-204.
12. Krol AD, Le Cessie S, Snijder S et al. Non-Hodgkin's lymphoma in the Netherlands: results from a population-based registry. Leuk Lymphoma 2003; 44: 451-458.
13. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004; 22: 4626-4631.
14. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005; 23: 3112-3124.
15. Piccirillo JF, Tierney RM, Costas I et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441-2447.
16. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
17. Common Terminology Criteria for Adverse Events. NIH Publication 2006.
18. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymfoid Tissues. Lyon, France: IARC 2008.
19. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
20. Bairey O, Benjamini O, Blickstein D et al. Non-Hodgkin's lymphoma in patients 80 years of age or older. Ann Oncol 2006; 17: 928-934.
21. Lichtman SM. Guidelines for the treatment of elderly cancer patients. Cancer Control 2003; 10: 445-453.
22. Mora O, Zucca E. Management of elderly patients with hematological neoplasms. Ann Oncol 2007; 18 (Suppl 1): i49-i53.
23. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003; 1: 18-24.
24. Thieblemont C, Grossoeuvre A, Houot R et al. Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 2008; 19: 774-779.
25. Morrison VA. Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma. Expert Rev Anticancer Ther 2008; 8: 1651-1658.
26. Doorduijn J, Buijt I, Holt B et al. Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol 2005; 75: 116-123.
27. Repetto L, Fratino L, Audisio RA et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20: 494-502.
28. Overcash JA, Beckstead J, Moody L et al. The abbreviated comprehensive geriatric assessment (aCGA) for use in the older cancer patient as a prescreen: scoring and interpretation. Crit Rev Oncol Hematol 2006; 59: 205-210.
29. Saliba D, Elliott M, Rubenstein LZ et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001; 49: 1691-1699.
30. Extermann M, Chen H, Cantor AB et al. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer 2002; 38: 1466-1473.
31. Extermann M, Overcash J, Lyman GH et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582-1587.
32. Janssen-Heijnen ML, Houterman S, Lemmens VE et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 2005; 55: 231-240.
33. Read WL, Tierney RM, Page NC et al. Differential prognostic impact of comorbidity. J Clin Oncol 2004; 22: 3099-3103.
34. Maartense E, Kluin-Nelemans HC, Le Cessie S et al. Different age limits for elderly patients with indolent and aggressive non-hodgkin lymphoma and the role of relative survival with increasing age. Cancer 2000; 89: 2667-2676.
35. Doorduijn JK, van der Holt B, van Imhoff GW et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 3041-3050.